Chaetoglobosin F, a small molecule compound, possesses immunomodulatory properties on bone marrow-derived dendritic cells via TLR9 signaling pathway.
Chunyan Hua, Yonghong Yang, Lin Sun, Huan Dou, Renxiang Tan, Yayi Hou
文献索引:Immunobiology 218(3) , 292-302, (2013)
全文:HTML全文
摘要
Chaetoglobosin F (Cha F), a cytochalasan-based alkaloid, was obtained from the EtOAc extract of a solid culture of Chaetomium globosum IFB-E019. Dendritic cells (DCs), the most potent antigen presenting cells, are considered as the major target in the modulation of excessive immune responses. Recognition of CpG-DNA by Toll-like receptor 9 (TLR9) on DCs is an important step in the pathogenesis of autoimmune diseases. However, the effect of Cha F on the maturation and immunostimulatory function of CpG-stimulated DCs remains unclear. This study investigated the effects of Cha F on bone marrow (BM)-derived DCs. We found that Cha F inhibits the CpG-induced DCs maturation and function by suppressing the expression of surface molecules (CD40, CD80, CD86 and MHC-II), reducing the production of cytokines and chemokines (IL-12 and CXCL-10), inhibiting the CpG-induced DCs-elicited allogeneic T-cell proliferation, and impairing the migration ability to chemokines. The Cha F-treated DCs were highly efficient at Ag capture, via mannose receptor-mediated endocytosis. Additionally, Cha F was also demonstrated to inhibit CpG-induced activation of MAPKs (p38 and JNK, but not ERK) and the nuclear translocation of NF-κB and STAT1. Furthermore, we confirmed that Cha F was able to suppress TLR9 expression of CpG-induced DCs. Collectively, these findings provide novel insight into the immunopharmacological functions of Cha F, especially with regard to their impact on CpG-induced DCs. These immunosuppressive properties of Cha F may prove useful in controlling DCs-associated autoimmune and/or inflammatory diseases.Copyright © 2012 Elsevier GmbH. All rights reserved.
相关化合物
相关文献:
2002-08-01
[Biochim. Biophys. Acta 1846(2) , 599-616, (2014)]
2015-01-28
[Cancer Lett. 356(2 Pt B) , 418-33, (2015)]
2008-06-01
[Pharm. Res. 25(6) , 1297-308, (2008)]
2007-07-01
[Mycopathologia 164(1) , 49-56, (2007)]
2012-09-30
[Rapid Commun. Mass Spectrom. 26(18) , 2115-22, (2012)]